FGAM
RXRX icon

Financial Gravity Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Financial Gravity Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$43 – 1723
2024
Q1 		$43 Buy
4
+3
+300% +$33 ﹤0.01% 1060
2023
Q4 		$13 Buy
+1
New +$7 ﹤0.01% 1259

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Financial Gravity Asset Management's RXRX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 4 shares — an estimated $43 sold.

Financial Gravity Asset Management first reported a position in RXRX in Q4 2023 and held it in 2 quarters. The position peaked at $43 in Q1 2024. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 4 Recursion Pharmaceuticals shares in Q2 2024, an estimated $43.
  • Financial Gravity Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Financial Gravity Asset Management's Recursion Pharmaceuticals position peaked at $43 in Q1 2024.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.